Related Experiment Video
Updated: Mar 12, 2026

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro
Published on: January 31, 2022
Drug Hepatotoxicity: Newer Agents.
Chalermrat Bunchorntavakul1, K Rajender Reddy2
1Division of Gastroenterology and Hepatology, Department of Medicine, University of Pennsylvania, 2 Dulles, 3400 Spruce Street, HUP, Philadelphia, PA 19104, USA; Division of Gastroenterology and Hepatology, Department of Medicine, Rajavithi Hospital, College of Medicine, Rangsit University, Rajavithi Road, Ratchathewi, Bangkok 10400, Thailand.
Newer medications, including tyrosine kinase inhibitors and monoclonal antibodies, show lower rates of drug-induced liver injury (DILI). However, severe liver damage cases still occur with some novel agents.
Area of Science:
- Pharmacology
- Hepatology
- Drug Safety
Background:
- Idiosyncratic hepatotoxicity is a significant cause for drug restrictions.
- Recent drug approvals include tyrosine kinase inhibitors, monoclonal antibodies, novel oral anticoagulants, and others.
- Understanding the liver safety profile of new medications is crucial.
Purpose of the Study:
- To review the hepatotoxicity of selected recently introduced drug classes.
- To compare the incidence of clinically relevant hepatotoxicity of newer agents versus older ones.
- To identify specific newer agents associated with severe liver injury.
Main Methods:
- Literature review focusing on recent drug approvals and their reported hepatotoxicity.
- Analysis of case reports and clinical trial data for specific drug classes.
- Identification of drugs with documented severe idiosyncratic hepatotoxicity.
Main Results:
- The overall incidence of clinically relevant hepatotoxicity appears lower for newer agents compared to older ones.
- Severe hepatotoxicity cases have been reported for several newer agents.
- Specific drugs like trastuzumab, ipilimumab, imatinib, and dabigatran are noted for potential liver injury.
Conclusions:
- While newer drug classes may have a better overall hepatotoxicity profile, vigilance is required.
- Severe idiosyncratic liver injury can occur with novel therapeutics.
- Continued monitoring and reporting of drug-induced liver injury are essential for patient safety.
More Related Videos
Related Concept Videos
Drug Toxicity: Overview
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Drug Toxicity: Risk factors
Hepatic Drug Excretion: Influencing Factors
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

